scholarly journals Quality of Life in Patients after Long-Term Biochemical Cure of Cushing’s Disease

2005 ◽  
Vol 90 (6) ◽  
pp. 3279-3286 ◽  
Author(s):  
M. O. van Aken ◽  
A. M. Pereira ◽  
N. R. Biermasz ◽  
S. W. van Thiel ◽  
H. C. Hoftijzer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Cushing's Disease ◽  
Biochemical Cure

scholarly journals Bilateral adrenalectomy in Cushing's disease: Altered long-term quality of life compared to other treatment options

2019 ◽  
Vol 80 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Pauline Sarkis ◽  
Muriel Rabilloud ◽  
Jean-Christophe Lifante ◽  
Anna Siamand ◽  
Emmanuel Jouanneau ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Treatment Options ◽  
Bilateral Adrenalectomy ◽  
Cushing's Disease

scholarly journals Quality of Life in Cushing's disease: A long term issue?

2018 ◽  
Vol 79 (3) ◽  
pp. 132-137 ◽  
Author(s):  
Susan M. Webb ◽  
Alicia Santos ◽  
Eugenia Resmini ◽  
Maria-Antonia Martínez-Momblán ◽  
Luciana Martel ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Cushing's Disease

Long-term negative impact on quality of life in patients with successfully treated Cushing's disease

2004 ◽  
Vol 61 (4) ◽  
pp. 458-465 ◽  
Author(s):  
Adrian H. Heald ◽  
Sandip Ghosh ◽  
Stephanie Bray ◽  
Christine Gibson ◽  
Simon G Anderson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Negative Impact ◽  
Cushing's Disease

scholarly journals Cushing’s Disease – Quality of Life, Recurrence and Long-term Morbidity

2015 ◽  
Vol 11 (1) ◽  
pp. 34 ◽  
Author(s):  
Isabel Huguet ◽  
Georgia Ntali ◽  
Ashley Grossman ◽  
Niki Karavitaki ◽  
◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Cushing's Disease ◽  
Recurrence Rates ◽  
Related Quality ◽  
Health Related ◽  
Acth Secreting

Cushing’s disease (CD) is a rare disorder caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma. Chronic exposure to hypercortisolism leads to significant morbidities, which may be only partially reversible after remission of the disease, as well as to impairment of the health-related quality of life (HRQoL) and an increase in mortality. Transsphenoidal surgery (TSS) is the treatment of choice, and recurrence rates vary widely, confirming the need for lifelong follow-up. This review summarises the studies performed on HRQoL, recurrence rates and morbidities in patients who have CD.

The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part II: normative data from 1784 healthy people

2012 ◽  
Vol 76 (6) ◽  
pp. 861-867 ◽  
Author(s):  
Monika Milian ◽  
Philipp Teufel ◽  
Juergen Honegger ◽  
Baptist Gallwitz ◽  
Guenter Schnauder ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Normative Data ◽  
Healthy People ◽  
Cushing's Disease ◽  
Quality Of Life Inventory ◽  
Life Inventory

scholarly journals Surgical management of pediatric Cushing's disease: an analysis of 15 consecutive cases at a specialized neurosurgical center

2010 ◽  
Vol 54 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Ricardo Santos de Oliveira ◽  
Margaret de Castro ◽  
Sonir Roberto Rauber Antonini ◽  
Carlos Eduardo Martinelli Júnior ◽  
Ayrton Custódio Moreira ◽  
...  
Keyword(s):  
Cushing’S Disease ◽  
Transsphenoidal Surgery ◽  
Pediatric Patients ◽  
Serum Cortisol ◽  
Plasma Cortisol Level ◽  
Hormone Deficiency ◽  
Cushing's Disease ◽  
Specialized Center ◽  
Biochemical Cure

OBJECTIVE: The aim of this study was to review the results of surgery for pediatric patients with Cushing's disease who were less than 18 years old and underwent transsphenoidal surgery in a specialized center during a 25-year period. SUBJECTS AND METHODS: Retrospective study, in which the medical records, histology and pituitary imaging of 15 consecutive pediatric patients with Cushing's disease (mean age: 13 years) were evaluated by the same team of endocrinologists and a neurosurgeon from 1982 to 2006. Patients were considered cured when there was clinical adrenal insufficiency and serum cortisol levels were below 1. 8 µg/dL or 50 nmol/L after one, two, three, or seven days following surgery; they therefore required cortisone replacement therapy. Follow-up was for a median time of 11.5 years (range: 2 to 25 years). RESULTS: Clinical and biochemical cure was achieved in 9/15 patients (60%) exclusively after transsphenoidal surgery. Hypopituitarism was observed in four patients; growth hormone deficiency, in two; permanent diabetes insipidus, in one case. CONCLUSIONS: Cushing's disease is rare in children and adolescents. Transsphenoidal surgery is an effective and safe treatment in most of these patients. Plasma cortisol level < 1. 8 µg/dL following surgery is the treatment goal and is a good predictive factor for long-term cure of Cushing's disease.

scholarly journals Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease

2014 ◽  
Vol 171 (1) ◽  
pp. 89-98 ◽  
Author(s):  
Susan M Webb ◽  
John E Ware ◽  
Anna Forsythe ◽  
Min Yang ◽  
Xavier Badia ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Treatment Effectiveness ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Cushing's Disease ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

ObjectiveCushing's disease (CD) can significantly impair patients' health-related quality of life (HRQOL). This study investigated the treatment effectiveness of pasireotide on HRQOL of CD patients, and assessed the relationships between HRQOL and urinary free cortisol (UFC) and CD-related signs and symptoms.DesignIn this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily. The trial primary endpoint was UFC at or below ULN at month 6 without dose titration. Open-label treatment continued through month 12. HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.MethodsPearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed. Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6. Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.ResultsChange in CushingQoL was significantly correlated with changes in mUFC (r=−0.40), BMI (r=−0.39), weight (r=−0.41), and BDI-II (r=−0.54) at month 12 but not at month 6. The percentage of CushingQoL responders at month 12 based on month 6 mUFC control status were as follows: 63, 58.8, and 37.9% in the controlled, partially controlled, and uncontrolled groups respectively. Adjusted CushingQoL scores at month 12 were 58.3 for controlled patients (Δ=11.5 vs uncontrolled,P=0.012) and 54.5 for partially controlled patients (Δ=7.7 vs uncontrolled,P=0.170).ConclusionsPasireotide treatment can result in a meaningful HRQOL improvement among those who complete a 12-month treatment period, most often among patients achieving biochemical control.

Sign in / Sign up

Export Citation Format

Share Document